| Today’s Big NewsFeb 14, 2024 |
|
Wednesday, February 28, 2024 | 11am ET / 8am PT While oral minitablets can offer several advantages in pharmaceutical applications, manufacturing them can be a complex challenge. Join industry experts for a discussion on the intricate journey of drug development, with a look at how minitablets have redefined formulation strategies, efficacy, patient-centric solutions, options for lifecycle management, and more. Sign up now! 
|
|
| By Angus Liu Biogen’s business has been in decline thanks to fierce multiple sclerosis competition and a botched Alzheimer’s drug launch. To make matters worse, the U.S. Department of Justice is looking into the company’s foreign operations. |
|
|
|
By James Waldron Before being swayed by antibody-drug conjugates, one of GSK’s passion projects was oligonucleotides. As part of this romance, the British Big Pharma signed a research collaboration with Elsie Biotechnologies last summer and has now decided to cement the relationship on Valentine’s Day. |
By Andrea Park The rumors are true: A week after reports first surfaced that Invitae was on the brink of filing for bankruptcy, the genetic testing company has done exactly that. |
By Angus Liu It’s the approval Ipsen has been waiting for since buying up Onivyde in 2017. The FDA has approved Onivyde as part of a combination dubbed Nalirifox to treat patients with newly diagnosed metastatic pancreatic cancer. |
|
Thursday, March 21, 2024 | 11am ET / 8am PT Join us for a discussion on the evolution of HCP engagement through the lens of Customer Science – the integration of data science, behavioral science, and AI. In this webinar, we explore how Customer Science brings substantial benefits to commercial leaders, providing a deeper understanding of HCPs and patients for more effective engagement. Register now. 
|
|
By Kevin Dunleavy The FDA has approved the first medicine for severe frostbite. The U.S. regulator has signed off on Eicos Sciences' Aurlumyn (iloprost), an injected treatment to reduce the risk of amputation of the fingers or toes. |
By Max Bayer Vertex may be the front-runner in the pursuit of a new non-opioid pain option, but one new biotech is emerging from stealth to mount a challenge with $135 million and a phase 1 clinical candidate. |
By Conor Hale Built on the design of the company’s top-selling MitraClip aimed at mitral valve regurgitation, the TriClip aims to repair the trickier valve on the opposite side of the heart. |
By Angus Liu Sage Therapeutics and Biogen may not have the broad label that they had hoped for with Zurzuvae, but the two companies are touting the med’s initial launch performance in postpartum depression. |
By Gabrielle Masson Earlybird Health is taking flight with 173 million euros ($186 million), a nest egg that will go toward European healthcare companies ranging from early development to late-stage tech nearing regulatory approval and commercialization. |
By Fraiser Kansteiner Even as Australia’s CSL continues to grow, the company’s ambitions for its kidney disease and iron deficiency outfit Vifor Pharma—now known as CSL Vifor—have become more muted. |
By Andrea Park Only about a year after earning its first FDA nod, Wandercraft’s Atalante X robotic exoskeleton has broadened that clearance. |
Fierce podcasts Don’t miss an episode |
| This week on "Podnosis," Fierce Healthcare's Paige Minemyer, Dave Muoio and Noah Tong share insights into this year's Fierce 15, discussing the companies that made the cut and the important issues they're addressing. |
|
|---|
|
|
Whitepaper This paper offers a detailed review of key events and developments in the oncology market during 2023. It’s a helpful “status report” that informs how the market is likely to evolve in 2024. It covers, vaccines, radiopharmaceuticals, ADCs, CAR-Ts, bi-specifics, & more. Presented by Blue Matter, strategic consultants in the life sciences |
Whitepaper Discover how to effectively classify highly potent APIs and the steps required to develop containment protocols and manufacturing processes that are both safe and efficient. Sponsored by: Catalent |
| |
|
